In a nutshell This study examined the risk of heart-related mortality in patients undergoing androgen-deprivation therapy (ADT) for prostate cancer. It found that patients treated with radiation therapy and ADT did not have an increased risk of heart-related mortality. Some background Prostate cancer is often treated with radiation therapy to...
Read More
In a nutshell This article reviewed the common side effects of estrogen deprivation during hormonal therapy for women with breast cancer and provided an update on alternative therapies to manage these symptoms. Some background Breast cancer (BC) is one of the most common cancers affecting women worldwide. Some BC cells grow in response to female...
Read More
In a nutshell The study compared patient-reported outcomes (PRO) in patients receiving continuous androgen deprivation therapy (CADT) vs intermittent androgen deprivation therapy (IADT) for locally advanced prostate cancer (PCa). The study reported that PROs were significantly improved with IADT. Some background ADT is a hormonal therapy...
Read More
In a nutshell This study evaluated patient-reported outcomes in men with non-metastatic castration-resistant prostate cancer (CRPC) when treated with either enzalutamide (Xtandi) or a placebo. The data showed that enzalutamide treatment delayed the time until pain progression and improved the quality of life of patients compared to a placebo. Some...
Read More
In a nutshell The study compared the effectiveness of bicalutamide (Casodex) to enzalutamide (Xtandi), both in combination with androgen deprivation therapy (ADT) in men with metastatic hormone-sensitive prostate cancer (mHSPC). The comparison showed that enzalutamide with ADT improves the outcomes particularly in Black men with mHSPC. Some...
Read More
In a nutshell This study aimed to investigate the combination of alpelisib (Piqray) and fulvestrant (Faslodex) in patients with PIK3CA-mutated, hormone receptor-positive (HR+), human epidermal growth factor 2 (HER2) negative, advanced breast cancer (BC). This study concluded that this combination provided positive outcomes for...
Read More
In a nutshell This study observed the effect of different physical activities on measures like pain and cardiorespiratory fitness in patients receiving hormone therapy for breast cancer (BC). The study showed that aerobic and resistance training might positively impact cardiorespiratory fitness and pain in these patients. Some...
Read More
In a nutshell This trial is evaluating the effectiveness and safety of combining nivolumab (Opdivo) with docetaxel (Taxotere) and prednisone (Deltasone) in men with metastatic castration-resistant prostate cancer (mCRPC). The main outcomes to be evaluated will be survival without cancer worsening and overall survival. The details CRPC is a difficult...
Read More
In a nutshell This study investigated if treating patients who have prostate cancer with androgen receptor inhibitors (ARIs) increased their risk of falling and breaking their bones. The study found that patients who received ARI were more likely to have a fall or fracture compared to other treatments. Some background Prostate cancer (PCa)...
Read More
In a nutshell This study investigated the quality of life after treating patients with metastatic hormone-sensitive prostate cancer (mHSPC) with enzalutamide (Xtandi) in combination with hormone therapy. The study found that enzalutamide + hormone therapy improved the quality of life of patients, compared to hormone therapy...
Read More
In a nutshell The study evaluated whether Breast Cancer Index (BCI) can predict benefits from extended endocrine therapy (EET) in patients with hormone-receptor-positive (HR+) early-stage breast cancer (BC). The authors found that BCI can predict which patients would benefit from 10 years of EET. Some background Endocrine therapy (ET) prevents tumor...
Read More
In a nutshell This trial was carried out to analyze whether the length of time without treatment and the length of time without active disease influences the survival of patients with advanced breast cancer (ABC) spread to the bone taking palbociclib (Ibrance) plus hormonal therapy (HT). The authors concluded...
Read More
